• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Understanding post-COVID-19 interstitial lung disease (ILD): a new fibroinflammatory disease entity.

作者信息

Mehta Puja, Rosas Ivan O, Singer Mervyn

机构信息

Centre for Inflammation and Tissue Repair, Division of Medicine, UCL Respiratory, University College London (UCL), Rayne 9 Building, London, WC1E 6JF, UK.

Department of Rheumatology, University College London Hospital (UCLH), London, UK.

出版信息

Intensive Care Med. 2022 Dec;48(12):1803-1806. doi: 10.1007/s00134-022-06877-w. Epub 2022 Sep 8.

DOI:10.1007/s00134-022-06877-w
PMID:36074167
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9453725/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb86/9453725/f01e81aa5746/134_2022_6877_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb86/9453725/f01e81aa5746/134_2022_6877_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb86/9453725/f01e81aa5746/134_2022_6877_Fig1_HTML.jpg

相似文献

1
Understanding post-COVID-19 interstitial lung disease (ILD): a new fibroinflammatory disease entity.了解新型冠状病毒肺炎后间质性肺疾病（ILD）：一种新的纤维炎症性疾病实体。
Intensive Care Med. 2022 Dec;48(12):1803-1806. doi: 10.1007/s00134-022-06877-w. Epub 2022 Sep 8.
2
Pulmonary Sequelae of COVID-19: Focus on Interstitial Lung Disease.新型冠状病毒肺炎的肺部后遗症：关注间质性肺疾病。
Cells. 2023 Sep 8;12(18):2238. doi: 10.3390/cells12182238.
3
Contemporary Concise Review 2020: Interstitial lung disease.当代简明综述 2020：间质性肺疾病。
Respirology. 2021 Jun;26(6):604-611. doi: 10.1111/resp.14063. Epub 2021 Apr 28.
4
Antimelanoma Differentiation-Associated Gene 5 Antibody-Positive Interstitial Lung Disease After Vaccination With COVID-19 mRNA Vaccines.抗黑色素瘤分化相关基因 5 抗体阳性间质性肺病与 COVID-19 mRNA 疫苗接种后。
J Rheumatol. 2022 Oct;49(10):1158-1162. doi: 10.3899/jrheum.220259. Epub 2022 Jun 15.
5
COVID-19 Pneumonia Followed by Anti-signal Recognition Particle Antibody-positive Fibrosing Interstitial Lung Disease.COVID-19 肺炎后继发抗信号识别颗粒抗体阳性的纤维性间质性肺病。
Intern Med. 2023 May 1;62(9):1323-1328. doi: 10.2169/internalmedicine.8877-21. Epub 2023 Feb 8.
6
[When COVID-19 encounters interstitial lung disease: challenges and management].当新冠病毒遇到间质性肺疾病：挑战与管理
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Aug 12;43(8):633-638. doi: 10.3760/cma.j.cn112147-20200315-00339.
7
COVID-19 and acute exacerbation of interstitial lung disease.COVID-19 与间质性肺病急性加重。
Respir Investig. 2021 Sep;59(5):675-678. doi: 10.1016/j.resinv.2021.06.007. Epub 2021 Jun 30.
8
Interstitial lung disease increases susceptibility to and severity of COVID-19.间质性肺疾病增加了感染 COVID-19 的易感性和严重程度。
Eur Respir J. 2021 Dec 2;58(6). doi: 10.1183/13993003.04125-2020. Print 2021 Dec.
9
Pre-existing interstitial lung disease in patients with coronavirus disease 2019: A meta-analysis.新型冠状病毒 2019 患者的预先存在的间质性肺病：一项荟萃分析。
Int Immunopharmacol. 2021 Nov;100:108145. doi: 10.1016/j.intimp.2021.108145. Epub 2021 Sep 9.
10
Post-COVID interstitial lung disease in symptomatic patients after COVID-19 disease.COVID-19 后症状性疾病患者的 COVID-19 后间质性肺病。
Inflammopharmacology. 2023 Apr;31(2):565-571. doi: 10.1007/s10787-023-01191-3. Epub 2023 Mar 24.

引用本文的文献

1
A dual role of fibroblast-epithelial crosstalk in acute and chronic lung injury.成纤维细胞-上皮细胞相互作用在急性和慢性肺损伤中的双重作用。
J Biol Chem. 2025 Jun 26;301(8):110408. doi: 10.1016/j.jbc.2025.110408.
2
The respiratory microbiome in patients with post-COVID-19 residual lung abnormalities resembles that of healthy individuals and is distinct from idiopathic pulmonary fibrosis.新冠后肺部残留异常患者的呼吸道微生物群与健康个体相似，且与特发性肺纤维化不同。
ERJ Open Res. 2025 May 27;11(3). doi: 10.1183/23120541.00826-2024. eCollection 2025 May.
3
Cytoimmunological Profile of Lower Airways in Post-COVID-19 Syndrome (PCS): Predictive Value of Bronchoalveolar Lavage.

本文引用的文献

1
COVID-19 lung disease shares driver AT2 cytopathic features with Idiopathic pulmonary fibrosis.COVID-19 肺病与特发性肺纤维化具有相同的驱动 AT2 细胞病变的特征。
EBioMedicine. 2022 Aug;82:104185. doi: 10.1016/j.ebiom.2022.104185. Epub 2022 Jul 20.
2
Imaging Glioblastoma Metabolism by Using Hyperpolarized [1-C]Pyruvate Demonstrates Heterogeneity in Lactate Labeling: A Proof of Principle Study.利用 1-¹³C 标记的丙酮酸对脑胶质瘤代谢进行成像显示乳酸标记的异质性：一项原理验证研究。
Radiol Imaging Cancer. 2022 Jul;4(4):e210076. doi: 10.1148/rycan.210076.
3
Long COVID: aiming for a consensus.
新冠后综合征（PCS）下呼吸道的细胞免疫特征：支气管肺泡灌洗的预测价值
J Clin Med. 2025 May 12;14(10):3361. doi: 10.3390/jcm14103361.
4
Distinct type 1 immune networks underlie the severity of restrictive lung disease after COVID-19.不同的1型免疫网络是新冠病毒感染后限制性肺病严重程度的基础。
Nat Immunol. 2025 Apr;26(4):595-606. doi: 10.1038/s41590-025-02110-0. Epub 2025 Mar 26.
5
Real-world evidence of remdesivir in formerly hospitalized COVID-19 patients: patient-reported and functional outcomes.瑞德西韦用于曾住院的COVID-19患者的真实世界证据：患者报告的结果和功能结局
BMC Infect Dis. 2025 Jan 9;25(1):43. doi: 10.1186/s12879-024-10398-w.
6
Understanding of Patients with Severe COVID-19 Using Lung Ultrasound.使用肺部超声对重症新型冠状病毒肺炎患者的认识
Tuberc Respir Dis (Seoul). 2025 Apr;88(2):380-387. doi: 10.4046/trd.2024.0025. Epub 2025 Jan 6.
7
Process-Specific Blood Biomarkers and Outcomes in COVID-19 Versus Non-COVID-19 ARDS (APEL-COVID Study): A Prospective, Observational Cohort Study.新型冠状病毒肺炎与非新型冠状病毒肺炎急性呼吸窘迫综合征的特定病程血液生物标志物及预后（APEL-COVID研究）：一项前瞻性观察性队列研究
J Clin Med. 2024 Oct 4;13(19):5919. doi: 10.3390/jcm13195919.
8
COVID-19-related Pneumonitis in Immunocompromised Patients: Reviewing Clinical Features and Management Approaches.免疫功能低下患者的新型冠状病毒肺炎相关肺炎：临床特征与管理方法综述
J Community Hosp Intern Med Perspect. 2024 Sep 9;14(5):63-72. doi: 10.55729/2000-9666.1399. eCollection 2024.
9
Diagnostic performance of radiologists in distinguishing post-COVID-19 residual abnormalities from interstitial lung abnormalities.放射科医生区分新冠病毒感染后残留异常与间质性肺异常的诊断效能。
Eur Radiol. 2025 Apr;35(4):2265-2274. doi: 10.1007/s00330-024-11075-x. Epub 2024 Sep 23.
10
Cardiovascular abnormalities of long-COVID syndrome: Pathogenic basis and potential strategy for treatment and rehabilitation.长新冠综合征的心血管异常：发病机制及治疗与康复的潜在策略
Sports Med Health Sci. 2024 Mar 24;6(3):221-231. doi: 10.1016/j.smhs.2024.03.009. eCollection 2024 Sep.
长期新冠：寻求共识。
Lancet Respir Med. 2022 Jul;10(7):632-634. doi: 10.1016/S2213-2600(22)00135-7. Epub 2022 May 4.
4
Prospective longitudinal evaluation of hospitalised COVID-19 survivors 3 and 12 months after discharge.对出院后3个月和12个月的COVID-19住院幸存者进行前瞻性纵向评估。
ERJ Open Res. 2022 Apr 11;8(2). doi: 10.1183/23120541.00004-2022. eCollection 2022 Apr.
5
Immuno-proteomic profiling reveals aberrant immune cell regulation in the airways of individuals with ongoing post-COVID-19 respiratory disease.免疫蛋白质组学分析揭示了持续性 COVID-19 呼吸道疾病患者气道中异常的免疫细胞调节。
Immunity. 2022 Mar 8;55(3):542-556.e5. doi: 10.1016/j.immuni.2022.01.017. Epub 2022 Jan 26.
6
SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis.SARS-CoV-2 感染引发成纤维细胞增生性巨噬细胞反应和肺纤维化。
Cell. 2021 Dec 22;184(26):6243-6261.e27. doi: 10.1016/j.cell.2021.11.033. Epub 2021 Nov 27.
7
The Promoter Polymorphism Associates With Severe COVID-19 in the European Population.启动子多态性与欧洲人群中的重症 COVID-19 相关。
Front Med (Lausanne). 2021 Nov 23;8:668024. doi: 10.3389/fmed.2021.668024. eCollection 2021.
8
The intersection of COVID-19 and autoimmunity.COVID-19 与自身免疫的交集。
J Clin Invest. 2021 Dec 15;131(24). doi: 10.1172/JCI154886.
9
Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study.利用 ISARIC WHO 临床特征协议 UK 对 COVID-19 相关院内并发症进行特征描述：一项前瞻性、多中心队列研究。
Lancet. 2021 Jul 17;398(10296):223-237. doi: 10.1016/S0140-6736(21)00799-6.
10
Is severe COVID-19 a cytokine storm syndrome: a hyperinflammatory debate.严重的 COVID-19 是否为细胞因子风暴综合征：一场过度炎症的争论。
Curr Opin Rheumatol. 2021 Sep 1;33(5):419-430. doi: 10.1097/BOR.0000000000000822.